Amount of qualified patients: CDEC talked over the uncertainty in the number of people with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as possessing mild or average ailment might have a severe https://hemgenix40482.alltdesign.com/everything-about-hemgenix-54775605